Treatment Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Treatment Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Treatment Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
CME, CPE, CE
Vijaya Raj Bhatt, MD; Mikkael A. Sekeres, MD
Release Date: October 16, 2020
Expiration Date: October 16, 2021

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are challenging for healthcare providers to treat and manage, partly because of the complexities surrounding diagnosis and prognosis, and because most patients are older. In this activity, two experts review cytogenetic and molecular abnormalities in AML and MDS, types of testing, and novel targets of treatment. They will also discuss case vignettes that support best practice for patients with AML and MDS.

This activity was previously presented between October 05 and 13, 2020 as a live webinar. Please note: If you participated in one of the live webinars, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Provided by University of Nebraska Medical Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals and Daiichi Sankyo.

Begin, Earn CreditView Only, No Credit